Results In For Pfizer Inc. (PFE) Rheumatoid Arthritis Study
Results for the Pfizer Inc.
Author Archive - Market Exclusive
CRT Devices From Medtronic PLC (MDT) Found To Be Cost-Effective
An economic analysis study done by Medtronic PLC.
Monday Movers In Biotech: Cempra Inc (CEMP) And IntelliPharmaCeutics Intl Inc (USA) (IPCI)
It’s going to be a good start to the week for a few companies in the biotech space, after a raft of positive news hit the wires on Friday.
With $12.2M In CIRM Funding, Caladrius Biosciences Inc (CLBS) Takes On Autoimmune Disease In Type I Diabetes
Autoimmune diseases account for the most prescriptions filled in the world. The most prescribed drug in the world today is levothyroxin for Hashimoto’s thyroiditis.
Here’s What Happened With Cyclacel Pharmaceuticals Inc (CYCC) And Nivalis Therapeutics Inc (NVLS)
This week was a good one for a few biotechs, but not so great for others.
Merck & Co., Inc. (MRK) In $2.9 Billion Writedown After Market For Hepatitis C Drug Market Shrinks
Merck & Co., Inc. (NYSE:MRK) has announced that it will be writing down approximately $2.9 billion following the shrinking of the market for a hepatitis drug it owns.
Boston Scientific Corporation (BSX) Lotus Transcatheter Recalled After Discovery Of Fault And Death Of One Patient
Boston Scientific Corporation (NYSE:BSX)'s Lotus transcatheter is being recalled due to a fault in the deployment of the system.
Trials Of Agenus Inc (AGEN) Cancer Vaccine Ends In Absolute Failure
Agenus Inc (NASDAQ:AGEN) has revealed that trials for a brain tumor vaccine have been halted after a lack of positive results.
Bristol-Myers Squibb Co (BMY) To Sell Senior Notes As Formidable Activist Investor Shows Interest
Bristol-Myers Squibb Co (NYSE:BMY) will sell senior notes that are unsecured worth $1.5 billion.
Gilead Sciences, Inc. (GILD) EPCLUSA Access To Be Provided In Ontario For Treatment Of Hepatitis C
Public access for Gilead Sciences, Inc. (NASDAQ:GILD) EPCLUSA will be provided in Ontario to adults who need the drug for the hepatitis C treatment.
Biotech Movers And Shakers: Ocular Therapeutix Inc (OCUL) And Argos Therapeutics Inc (ARGS)
The biotechnology space has been a pretty volatile arena over the last few weeks, and especially when it comes to the smaller capitalization end of the sector.
Boston Scientific Corporation (BSX) Loses On A $309M Appeal At US Supreme Court
An appeal by Boston Scientific Corporation (NYSE:BSX) has been declined by the U.S. Supreme Court.
Manufacturing Delay Of Generic Drug From Pfizer Inc. (PFE) A Relief For Teva Pharmaceutical Industries Ltd (ADR) (TEVA)
Pfizer Inc. (NYSE:PFE) has been slapped with a warning letter by the Food and Drug Administration in regards to one of its fill/finish factories.
Is The Cidara Therapeutics Inc (CDTX) Crash An Opportunity?
Cidara Therapeutics Inc (NASDAQ:CDTX) just announced data from a phase 2 study of one of its lead indications, and the outcome was unfavorable.
Here’s What The Latest Pain Therapeutics, Inc. (PTIE) Update Means
Pain Therapeutics, Inc.
AbbVie Inc (ABBV) In Share Buyback Plan For The Third Year In A Row
The AbbVie Inc (NYSE:ABBV) board of directors has given the authorization required to increase $5 billion to the company’s existing share buyback program.
Bristol-Myers Squibb Co (BMY), Merck & Co., Inc. (MRK), And Other Pharmaceutical Firms All Targeting I-O Segment
Reports indicate that the market for immuno-oncology drugs could grow to $25 billion in the next ten years.
ArQule, Inc. (ARQL)’s Liver Cancer Drug Fails: What’s Next?
ArQule, Inc. (NASDAQ:ARQL) took a real hit at the end of last week, as the company announced data from a late stage oncology trial.
Alexion Pharmaceuticals, Inc. (ALXN) Suffers Another Blow In The UK
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has had another misfortune in the UK.
It Has Worked: CVS Health Corp (CVS) Says Of Its Exit Of Cigarette Business
CVS Health Corp (NYSE:CVS) has published a study report in the American Journal of Public Health that shows its decision to halt the sale of tobacco products has had a tremendous...
Neuralstem, Inc. (CUR) Is Up. Here’s Why And What It Means
Neuralstem, Inc. (NASDAQ:CUR) is a big runner at the end of this week, as the company puts out an update on its lead major depressive disorder (MDD) trial.
Here’s What The Latest Ardelyx Inc (ARDX) Data Means For The Company Going Forward
Ardelyx Inc (NASDAQ:ARDX) just put out data from a phase III study in patients with end stage renal disease, and the company is running up on the back of the news.
Generic Competitors A Looming Threat For Acorda Therapeutics Inc (ACOR)
In order to ensure an extension of Ampyra’s protection to 2026, Acorda Therapeutics Inc (NASDAQ:ACOR) must fight off competition from competitors such as Roxane, Teva Pharmaceutical...
UK National Institute For Health And Care Excellence Rejects Leukemia Drug From AbbVie Inc (ABBV)
The National Institute for Health and Care Excellence has refused to authorize AbbVie Inc (NYSE:ABBV)'s Venclyxto on NHS.
The Market Has Got Its Interpretation Of The OHR Pharmaceutical Inc (OHRP) Announcement Wrong
OHR Pharmaceutical Inc (NASDAQ:OHRP) reported its fiscal first quarter 2017 earnings this week, and alongside the report, gave an update as to the status if its lead ocular study...
Medtronic PLC (MDT) Launches New Tools In Coronary Portfolio
Medtronic PLC (NYSE:MDT) launched new products that aim to help in diagnosis and treatment of coronary conditions.
China MediTech And AstraZeneca PLC (ADR) (AZN) To Present Savolitinib Phase II Results At The Genitourinary Cancers Symposium 2017
Hutchison China MediTech Limited and AstraZeneca plc (ADR) (NYSE:AZN) are to present data from their phase II clinical trials of Savolitinib, at the upcoming 2017 Genitourinary...
VBI Vaccines, Inc. (VBIV) Gets European Support For Pivotal Phase III Sci-B-Vac Trial
Risks in biotech investment tend to increase as a young company gets closer and closer to its first FDA approval.
GlaxoSmithKline PLC (ADR) (GSK) Two-Drug Cocktail Aims Decrease HIV Patient Pill Intake
Most HIV patients have no options in regard to how they must consume their medication.
Skin & Bones Of Regenerative Medicine Takes A Leap Forward With Frost Backing PolarityTE Inc. (COOL)
There are a few names in every sector that develop a reputation on the back of repeated investment success.
Novartis AG (ADR) (NVS) Greater Use Of Technology In Transforming Medical Education
Novartis AG (ADR) (NYSE:NVS) is quickly entering into an engagement with the use of digital technology.
Positive Results For MDD Drug Sends Shares Of SAGE Therapeutics Inc (SAGE) Soaring
Shares of SAGE Therapeutics Inc (NASDAQ:SAGE) surged after the results of a small, mid-stage study on major depressive disorder showed positive results.
Zosano Pharma Corp (ZSAN) Is Playing With The Big Boys In The Migraine Space
Zosano Pharma Corp (NASDAQ:ZSAN) gained more than 40% on its market capitalization during Monday’s US session, and is a further 9% up ahead of the market open on Tuesday.
Regeneron Pharmaceuticals Inc (REGN) and Sanofi SA (ADR) (SNY) Obtain Suspension of Injunction for Cholesterol Drug Sales
Correction: A previous version of this article erroneously presented older events about the case between Sanofi/Regeneron and Amgen.
Trulicity Label From Eli Lilly And Co (LLY) Will Be Used In Combination With Basal Insulin
The once per week Trulicity label from Eli Lilly and Co (NYSE:LLY) has been updated. The changes, which have been approved by the U.S.
Portola Pharmaceuticals Inc (PTLA) Just Scored Twice In Quick Succession
Portola Pharmaceuticals Inc (NASDAQ:PTLA) is riding high on the back of a couple of key announcements late this week.
Allergan PLC (AGN) Launches Campaign To Fight Preventable Blindness In America
Allergan Plc (NYSE:AGN) has launched a new initiative aimed at fighting preventable blindness in the United States.
FDA Approves Amgen, Inc. (AMGN) Drug For Treating Secondary Hyperparathyroidism
Etelcalcetide, an Amgen, Inc. (NASDAQ:AMGN) drug that is meant to treat secondary hyperparathyroidism has been approved by the U.S. Food and Drug Administration.
Coherus Biosciences Inc (CHRS) Could Be A Discount Entry On The Pullback
Coherus Biosciences Inc (NASDAQ:CHRS) just announced that it has kicked off a public offering that will se it unload $125 million worth of its common stock, alongside an additional...
Cellectis SA (ADR) (CLLS) Just Made A Big Step Forward In CAR-T
Cellectis SA (ADR) (NASDAQ:CLLS) just announced that the FDA has granted it approval to proceed with the clinical development of a drug called UCART123.
DelMar Pharmaceuticals Inc (DMPI) Moves Forward With Flagship Chemotherapy Into Phase II
We hear the word chemotherapy all the time. It’s a treatment associated with most cancers.
The FDA Accepts Keytruda From Merck & Co., Inc. (MRK) For Bladder Cancer
Patients with bladder cancer now having something to smile about, after the acceptance of 2 new supplemental biologics license applications, by the FDA.
What’s Next For Esperion Therapeutics Inc (ESPR)?
Esperion Therapeutics Inc (NASDAQ:ESPR) picked up strength at the end of last week, on the back of some news that – at first glance – seems unrelated to its own operations...
Pfizer Inc. (PFE) And Citibank To Work Together On $5 Billion Share Repurchase Program
Pfizer Inc. (NYSE:PFE) and Citibank have agreed to work together in the acceleration of share repurchase, which will involve buying back of Pfizer’s common stock.
Abbott Laboratories (ABT)’s Molecular Test For Detecting Zika Virus Approved By The FDA
The Abbott RealTime ZIKA molecular test from Abbott Laboratories (NYSE:ABT) has gained the approval of the U.S. Food and Drug Administration (FDA).
Pfizer Inc. (PFE)’s Breast Cancer Drug Too Expensive: Says NICE
The National Institute for Health and Care Excellence (NICE) has declared the latest breast cancer drug too expensive to justify its use.
Stemline Therapeutics Inc (STML): What’s The Other Side Of The Story?
Stemline Therapeutics Inc (NASDAQ:STML) is one of the biggest stories in the biotechnology space this week.
Price For Synergy Pharmaceuticals Inc (SGYP) Public Offering Announced
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has revealed that the price of its common stock through its upcoming public offering will be $6.15 a share.
What We’re Looking For From Summit Therapeutics PLC (ADR) (SMMT)
Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) is running up this week on an update relating to its lead C. Difficile infection asset, Ridinilazole.
